Literature DB >> 20570309

An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.

Jasminka Sterjovski1, Michael Roche, Melissa J Churchill, Anne Ellett, William Farrugia, Lachlan R Gray, Daniel Cowley, Pantelis Poumbourios, Benhur Lee, Steven L Wesselingh, Anthony L Cunningham, Paul A Ramsland, Paul R Gorry.   

Abstract

While CCR5 is the principal coreceptor used by macrophage (M)-tropic HIV-1, not all primary CCR5-using (R5) viruses enter macrophages efficiently. Here, we used functionally-diverse R5 envelope (Env) clones to characterize virus-cell interactions important for efficient CCR5-mediated macrophage entry. The magnitude of macrophage entry by Env-pseudotyped reporter viruses correlated with increased immunoreactivity of CD4-induced gp120 epitopes, increased ability to scavenge low levels of cell-surface CCR5, reduced sensitivity to the CCR5 inhibitor maraviroc, and increased dependence on specific residues in the CCR5 ECL2 region. These results are consistent with an altered and more efficient mechanism of CCR5 engagement. Structural studies revealed potential alterations within the gp120 V3 loop, the gp41 interaction sites at the gp120 C- and N-termini, and within the gp120 CD4 binding site which may directly or indirectly lead to more efficient CCR5-usage. Thus, enhanced gp120-CCR5 interactions may contribute to M-tropism of R5 HIV-1 strains through different structural mechanisms. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570309      PMCID: PMC3096480          DOI: 10.1016/j.virol.2010.05.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  84 in total

1.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice.

Authors:  R M Scoggins; J R Taylor; J Patrie; A B van't Wout; H Schuitemaker; D Camerini
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Antigenic variation in gp120s from molecular clones of HIV-1 LAI.

Authors:  J P Moore; H Yoshiyama; D D Ho; J E Robinson; J Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  1993-12       Impact factor: 2.205

4.  Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS.

Authors:  M Jansson; E Backström; A Björndal; V Holmberg; P Rossi; E M Fenyö; M Popovic; J Albert; H Wigzell
Journal:  J Hum Virol       Date:  1999 Nov-Dec

5.  Comparative protein modelling by satisfaction of spatial restraints.

Authors:  A Sali; T L Blundell
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

6.  Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo.

Authors:  B Etemad-Moghadam; Y Sun; E K Nicholson; M Fernandes; K Liou; R Gomila; J Lee; J Sodroski
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.

Authors:  R Collman; J W Balliet; S A Gregory; H Friedman; D L Kolson; N Nathanson; A Srinivasan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates.

Authors:  S Li; J Juarez; M Alali; D Dwyer; R Collman; A Cunningham; H M Naif
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

View more
  36 in total

Review 1.  Coreceptors and HIV-1 pathogenesis.

Authors:  Paul R Gorry; Petronela Ancuta
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

2.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.

Authors:  Nicole Espy; Beatriz Pacheco; Joseph Sodroski
Journal:  Virology       Date:  2017-05-15       Impact factor: 3.616

4.  Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Authors:  Zahra F Parker; Shilpa S Iyer; Craig B Wilen; Nicholas F Parrish; Kelechi C Chikere; Fang-Hua Lee; Chuka A Didigu; Reem Berro; Per Johan Klasse; Benhur Lee; John P Moore; George M Shaw; Beatrice H Hahn; Robert W Doms
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

5.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.

Authors:  Michael Roche; Martin R Jakobsen; Jasminka Sterjovski; Anne Ellett; Filippo Posta; Benhur Lee; Becky Jubb; Mike Westby; Sharon R Lewin; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

7.  CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Authors:  Olga Latinovic; Marvin Reitz; Nhut M Le; James S Foulke; Gerd Fätkenheuer; Clara Lehmann; Robert R Redfield; Alonso Heredia
Journal:  Virology       Date:  2011-01-12       Impact factor: 3.616

8.  CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4+ T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained.

Authors:  Michael Roche; Carolin Tumpach; Jori Symons; Matthew Gartner; Jenny L Anderson; Gabriela Khoury; Kieran Cashin; Paul U Cameron; Melissa J Churchill; Steven G Deeks; Paul R Gorry; Sharon R Lewin
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

9.  Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.

Authors:  Hamid Salimi; Michael Roche; Nicholas Webb; Lachlan R Gray; Kelechi Chikere; Jasminka Sterjovski; Anne Ellett; Steve L Wesselingh; Paul A Ramsland; Benhur Lee; Melissa J Churchill; Paul R Gorry
Journal:  J Leukoc Biol       Date:  2012-10-17       Impact factor: 4.962

Review 10.  Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV.

Authors:  Kelechi Chikere; Tom Chou; Paul R Gorry; Benhur Lee
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.